Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells

• Auteurs principaux: Mitsuki Tabata (Auteur), Masanobu Tsubaki (Auteur), Tomoya Takeda (Auteur), Keisuke Tateishi (Auteur), Katsumasa Tsurushima (Auteur), Motohiro Imano (Auteur), Takao Satou (Auteur), Toshihiko Ishizaka (Auteur), Shozo Nishida (Auteur)
• Format: Livre
• Publié: BMC, 2020-03-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract Background Current chemotherapies for Burkitt lymphoma (BL) have dramatically improved its clinical outcome. However, chemoresistance can lead to chemotherapy failure and very poor prognosis; thus, novel strategies are urgently required for patients with drug-resistant BL. To investigate th...